These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15467441)

  • 21. Synthesis and biological activity of enantiomers of antitumor irofulven.
    McMorris TC; Staake MD; Kelner MJ
    J Org Chem; 2004 Feb; 69(3):619-23. PubMed ID: 14750783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.
    Raymond E; Kahatt C; Rigolet MH; Sutherland W; Lokiec F; Alexandre J; Tombal B; Elman M; Lee MS; MacDonald JR; Cullen M; Misset JL; Cvitkovic E
    Clin Cancer Res; 2004 Nov; 10(22):7566-74. PubMed ID: 15569987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
    Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
    Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114).
    Woynarowski JM; Napier C; Koester SK; Chen SF; Troyer D; Chapman W; MacDonald JR
    Biochem Pharmacol; 1997 Dec; 54(11):1181-93. PubMed ID: 9416969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity studies of antitumor agent irofulven (hydroxymethylacylfulvene) and analogues.
    McMorris TC; Yu J; Lira R; Dawe R; MacDonald JR; Waters SJ; Estes LA; Kelner MJ
    J Org Chem; 2001 Sep; 66(18):6158-63. PubMed ID: 11529745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
    Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
    Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiosensitivity of thymidylate synthase-deficient human tumor cells is affected by progression through the G1 restriction point into S-phase: implications for fluoropyrimidine radiosensitization.
    Hwang HS; Davis TW; Houghton JA; Kinsella TJ
    Cancer Res; 2000 Jan; 60(1):92-100. PubMed ID: 10646859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.
    Friedman HS; Keir ST; Houghton PJ; Lawless AA; Bigner DD; Waters SJ
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):413-6. PubMed ID: 11761460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of bcl-2 and bax in TGF-beta 1-induced apoptosis of L1210 leukemic cells.
    Motyl T; Grzelkowska K; Zimowska W; Skierski J; Wareski P; Płoszaj T; Trzeciak L
    Eur J Cell Biol; 1998 Apr; 75(4):367-74. PubMed ID: 9628323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
    Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
    Paci A; Rezai K; Deroussent A; De Valeriola D; Re M; Weill S; Cvitkovic E; Kahatt C; Shah A; Waters S; Weems G; Vassal G; Lokiec F
    Drug Metab Dispos; 2006 Nov; 34(11):1918-26. PubMed ID: 16896064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
    Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
    Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells.
    Walker A; Taylor ST; Hickman JA; Dive C
    Cancer Res; 1997 May; 57(10):1939-45. PubMed ID: 9157989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy.
    Johnson KR; Young KK; Fan W
    Clin Cancer Res; 1999 Sep; 5(9):2559-65. PubMed ID: 10499633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer.
    Amato RJ; Perez C; Pagliaro L
    Invest New Drugs; 2002 Nov; 20(4):413-7. PubMed ID: 12448659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
    Koeppel F; Poindessous V; Lazar V; Raymond E; Sarasin A; Larsen AK
    Clin Cancer Res; 2004 Aug; 10(16):5604-13. PubMed ID: 15328203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
    Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
    Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. G(1) phase-dependent expression of bcl-2 mRNA and protein correlates with chemoresistance of human cancer cells.
    Gao G; Dou QP
    Mol Pharmacol; 2000 Nov; 58(5):1001-10. PubMed ID: 11040047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ganoderic acid Mf and S induce mitochondria mediated apoptosis in human cervical carcinoma HeLa cells.
    Liu RM; Zhong JJ
    Phytomedicine; 2011 Mar; 18(5):349-55. PubMed ID: 21036023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis.
    Demidenko ZN; Kalurupalle S; Hanko C; Lim CU; Broude E; Blagosklonny MV
    Oncogene; 2008 Jul; 27(32):4402-10. PubMed ID: 18469851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.